Intracellular Delivery of Oligonucleotide Conjugates and Dendrimer Complexes
- 1 October 2006
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1082 (1), 18-26
- https://doi.org/10.1196/annals.1348.011
Abstract
Enhancing the delivery of antisense and siRNA molecules to cells and tissues is a key issue for oligonucleotide therapeutics. Cell-penetrating peptides (CPPs) have the ability to convey linked "cargo" molecules into the cytosol; thus we have explored the use of CPPs as delivery agents for oligonucleotides. We have extensively evaluated CPP-oligonucleotide conjugates, and have recently begun to explore the use of CPP-dendrimer-oligonucleotide complexes. We have found that CPP-antisense oligonucleotide conjugates can be taken up by cells and can effectively modify gene expression in cell culture and in tissues. Although not as potent in cell culture as cationic lipid delivery agents, CPP-oligonucleotide conjugates offer the advantage of being molecules rather than particles, and may have substantial advantages over particle-based delivery in the in vivo setting.Keywords
This publication has 21 references indexed in Scilit:
- Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAsNature, 2004
- The use of cell-penetrating peptides as a tool for gene regulationDrug Discovery Today, 2004
- siRNAs: applications in functional genomics and potential as therapeuticsNature Reviews Drug Discovery, 2004
- Progress in Antisense TechnologyAnnual Review of Medicine, 2004
- Nanogels for Oligonucleotide Delivery to the BrainBioconjugate Chemistry, 2003
- Antisense technologiesEuropean Journal of Biochemistry, 2003
- Biodegradable nanoparticles for drug and gene delivery to cells and tissueAdvanced Drug Delivery Reviews, 2002
- Protein transduction technologyCurrent Opinion in Biotechnology, 2002
- Development of non-viral vectors for systemic gene deliveryJournal of Controlled Release, 2001
- Antisense Pharmacodynamics: Critical Issues in the Transport and Delivery of Antisense OligonucleotidesPharmaceutical Research, 1999